Luminous Ventures
VC Fund
London, United Kingdom
Luminous Ventures is a London-based VC fund investing in Deep Tech with a focus on the application of innovative technologies to healthcare, life science, nutrition, food and agriculture. Investing at Seed and Series A, Luminous has backed companies in Europe and North America.
- Total investments:
- 26
- Last investment:
- Lead investor:
- 42%
- Fund size:
- $28M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Luminous Ventures invests in
Stages Luminous Ventures invests in
Countries Luminous Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1M–$4.5M
- Series A
- $9.9M–$26M
- Venture - Series Unknown
- $3M–$9.5M
Investment Focus
Industry
- Software 7 (27%)
- Health Care 7 (27%)
- Artificial Intelligence 6 (23%)
- Machine Learning 4 (15%)
- Information Technology 4 (15%)
Stage
- Seed 10 (38%)
- Series A 3 (12%)
- Venture - Series Unknown 3 (12%)
- Funding Round 2 (8%)
- Pre-Seed 1 (4%)
Country
- United Kingdom 12 (46%)
- United States 2 (8%)
- Canada 1 (4%)
- Singapore 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Alasdair Thong
Venture Partner
|
Venture Partner | Total investments: 8 | Find email | |
Lomax Ward
Founding Partner
|
Founding Partner | Total investments: 7 | Find email | |
|
Miao He
Associate
|
Associate | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Ambi develops an ambient intelligence system that operates across wearable hardware, mobile devices, and cloud software. The system captures context, remembers relevant information, and helps convert intentions into follow-up actions. Its stated functions include supporting schedules, administrative tasks, reminders, and other personal workflows. Ambi is developing hardware for this system and is accepting early-access registrations before the planned hardware availability. | $26M / Seed / Oct 12, 2026 | ||
| Sage provides 24/7 support and simplified healthcare navigation, guiding patients through complex healthcare processes with empathetic conversation. | $26M / Series A / Jun 15, 2021 | ||
| Treos Bio, Inc. is a computational immunology and immunotherapy company which has developed a proprietary technology to predict in silico likely responders to cancer immunotherapies and to design in silico next generation targeted immunotherapies for a large population of cancer patients. | $16.4M / Convertible Note / Mar 31, 2021 | ||
| LGN is a developer of artificial perception technology used to balance and automatically connect the AI system to the sensor array. Its technology reduces capture and processing costs by automatically filtering data to only record and process edge cases and by transferring and storing data in a highly compressed form that enable industries with areduced chip cost and power consumption whilst allowing high-level autonomy on lower-cost commodity sensors. | $1.9M / Seed / Mar 23, 2021 | ||
| Universal Quantum is building quantum computers to tackle real-world problems that would take today’s fastest supercomputers billions of years to solve. | $4.5M / Seed / Jun 14, 2020 | ||
| Oxford VR is a spin out from Oxford University built on the work of Professor Daniel Freeman who has been developing effective VR-based mental health treatments for 15 years. Ground-breaking research, combined with the advent of highly immersive consumer VR, means that we can provide to millions treatments that are: faster and more effective thantraditional treatments; significantly lower cost to health providers; loved by users. Our focus is on developing clinically validated, cost-effective, user-centred treatments for clinical conditions with significant impact on patients, the health system and wider economy. | $13M / Series A / Feb 12, 2020 | ||
| LGN is a developer of artificial perception technology used to balance and automatically connect the AI system to the sensor array. Its technology reduces capture and processing costs by automatically filtering data to only record and process edge cases and by transferring and storing data in a highly compressed form that enable industries with areduced chip cost and power consumption whilst allowing high-level autonomy on lower-cost commodity sensors. | $615.6K / Oct 31, 2019 | ||
| LGN is a developer of artificial perception technology used to balance and automatically connect the AI system to the sensor array. Its technology reduces capture and processing costs by automatically filtering data to only record and process edge cases and by transferring and storing data in a highly compressed form that enable industries with areduced chip cost and power consumption whilst allowing high-level autonomy on lower-cost commodity sensors. | $615.6K / Seed / Oct 31, 2019 | ||
| Optellum develops an imaging biomarker for smart lung cancer detection. Optellum’s vision is to redefine cancer care, by enabling every clinician, in every hospital, to manage their patients in the optimal way. They do that by providing end-end IT platform for personalized early diagnosis and therapy, based on the collective experience ofthousands of doctors pooled by machine learning applied to vast patient datasets. Their first suite of products targets management of patients at high risk of developing lung cancer – the world’s deadliest and commonest cancer – from early diagnosis through to treatment. Optellum comprises a team of award-winning medical imaging software, AI, and clinical experts who met at Oxford’s world-renowned computer vision lab. Between us, they have track records of bringing innovation to market through over 10 start-up companies, resulting already in 5 trade-sales and one IPO. They are backed by an Advisory Board comprising world-leading clinicians and experts in deep learning ; and Oxford's most prominent investors. They are building up their product development team – join their fight against cancer, working together with former software engineers from top technology companies (Amazon, Facebook, Redhat) and veterans of medical imaging startups (e.g. Mirada Solutions – acquired by Siemens). | $1.3M / Seed / Jul 16, 2019 | ||
| Astroscreen protects brands and defends democracy from harmful social media manipulation campaigns also known as astroturfing. | $1M / Seed / Apr 18, 2019 | ||
| See all 26 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Luminous Ventures invest in?
Luminous Ventures invests primarily in Software, Health Care and Artificial Intelligence startups, most often at Seed and Series A stage. Most of the 26 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Luminous Ventures invest in?
Luminous Ventures typically joins rounds of $1M–$4.5M at Seed, $9.9M–$26M at Series A and $3M–$9.5M at Venture - Series Unknown. These are whole funding-round sizes, not Luminous Ventures's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Luminous Ventures took part in.
How do I contact Luminous Ventures?
Public channels for Luminous Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Luminous Ventures?
The team at Luminous Ventures includes Alasdair Thong (Venture Partner), Lomax Ward (Founding Partner) and Miao He (Associate). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
